Atika Capital Management LLC Biomarin Pharmaceutical Inc Call Options Transaction History

Atika Capital Management LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2021 Aug 12, 2021	SELL	$75.51 - $84.79 $54,367 - $61,048	-720 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$74.73 - $90.69 $5.33 Million - $6.46 Million	-71,280 Reduced 99.0%	720 $5.44 Million
Q4 2020 Feb 16, 2021	SELL	$72.61 - $90.2 $1.31 Million - $1.62 Million	-18,000 Reduced 20.0%	72,000 $6.31 Million
Q2 2020 Aug 13, 2020	BUY	$79.55 - $124.22 $6.38 Million - $9.96 Million	80,200 Added 818.37%	90,000 $11.1 Million
Q4 2018 Feb 14, 2019	SELL	$80.14 - $106.07 $3.37 Million - $4.47 Million	-42,100 Reduced 81.12%	9,800 $835,000
Q3 2018 Nov 14, 2018	SELL	$93.92 - $105.72 $469,600 - $528,600	-5,000 Reduced 8.79%	51,900 $5.03 Million
Q2 2018 Aug 14, 2018	BUY	$76.01 - $99.03 $3.08 Million - $4.01 Million	40,500 Added 246.95%	56,900 $5.36 Million
Q1 2018 May 15, 2018	BUY	$77.67 - $92.63 $1.27 Million - $1.52 Million	16,400 New	16,400 $1.33 Million

635

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $11.8B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Atika Capital Management LLC with notifications on news.